Spots Global Cancer Trial Database for Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
Official Title: A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies
Study ID: NCT02189174
Conditions
Interventions
Study Description
Brief Summary: To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Massachusetts General Hospital SC-9, Boston, Massachusetts, United States
Memorial Sloan Kettering SC-4, New York, New York, United States
Tennessee Oncology SC, Nashville, Tennessee, United States
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
